Pembrolizumab results posted for advanced gynecologic clear cell cancer

ClinicalTrials.gov posted results on 22 September 2026 for a study of pembrolizumab in advanced gynaecological clear cell cancer. The completed Phase II trial enrolled 48 participants; the registry reported a best objective response rate of 25% and median progression-free survival of 2.7 months.

Background

The PEACOCC study evaluated pembrolizumab in patients with advanced clear cell gynaecological cancer. Its registry summary describes the trial’s aim as determining whether treatment with pembrolizumab was effective in this population. The listed conditions were clear cell tumor, gynecologic cancer and advanced cancer. The supplied record does not provide information about pembrolizumab’s mechanism, prior approvals or disease prevalence.

Trial design

This completed Phase II study, identified as NCT03425565, was a multi-centre, single-arm, single-stage trial with 48 participants. Pembrolizumab was the listed intervention. The record contains no primary-outcome entries and lists no comparator arm, so the posted measurements are not comparative results.

Key results

At 12 weeks, progression-free survival was reported for 42% of participants, while objective response was reported for 21%. The best objective response rate was 25%. Median progression-free survival was 2.7 months, and median overall survival was 14.8 months. The registry labels confidence intervals for these measurements but supplies no numerical interval values.

Median duration of response was 13.1 months. The record also reports 7.1 months for time to second disease progression during the re-treatment period. For quality of life, the mean change in the FACT-O total score was −6.7 points, with a standard deviation of 20.88. Mean changes in physical, social, emotional and functional well-being scores were −1.3 (SD 5.40), −1.3 (SD 3.43), −0.3 (SD 4.29) and −1.8 (SD 6.72), respectively. No p-values or key analyses were supplied.

What this means

The posted results provide response, survival and quality-of-life measurements for a single-arm study, but do not show how pembrolizumab performed against another treatment. The absence of a comparator, numerical confidence intervals and listed primary-outcome entries limits interpretation; the reported figures alone do not establish comparative benefit.

Source

Source: ClinicalTrials.gov, registry results for “A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer,” posted 22 September 2026. Available at clinicaltrials.gov/study/NCT03425565.